This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. RARE, MTSR, VKTX, AKRO, CPRX, CRNX, MRUS, MOR, PTGX, and MLTXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Ultragenyx Pharmaceutical (RARE), Metsera (MTSR), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), MorphoSys (MOR), Protagonist Therapeutics (PTGX), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Ultragenyx Pharmaceutical Metsera Viking Therapeutics Akero Therapeutics Catalyst Pharmaceuticals Crinetics Pharmaceuticals Merus MorphoSys Protagonist Therapeutics MoonLake Immunotherapeutics Ultragenyx Pharmaceutical (NASDAQ:RARE) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership. Is RARE or RTRX more profitable? Travere Therapeutics has a net margin of -49.13% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Travere Therapeutics' return on equity of -36.38% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical-101.60% -193.80% -38.15% Travere Therapeutics -49.13%-36.38%-14.90% Do institutionals & insiders have more ownership in RARE or RTRX? 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 4.6% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, RARE or RTRX? Ultragenyx Pharmaceutical has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Does the media prefer RARE or RTRX? In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Travere Therapeutics. MarketBeat recorded 11 mentions for Ultragenyx Pharmaceutical and 1 mentions for Travere Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 1.53 beat Travere Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Travere Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in RARE or RTRX? Ultragenyx Pharmaceutical received 419 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 77.54% of users gave Ultragenyx Pharmaceutical an outperform vote while only 73.17% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformUltragenyx PharmaceuticalOutperform Votes83977.54% Underperform Votes24322.46% Travere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Which has stronger earnings and valuation, RARE or RTRX? Travere Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUltragenyx Pharmaceutical$590.69M5.71-$569.18M-$5.88-6.06Travere Therapeutics$175.34M4.57-$146.43M-$3.46-4.54 Do analysts prefer RARE or RTRX? Ultragenyx Pharmaceutical presently has a consensus target price of $90.93, suggesting a potential upside of 155.00%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryUltragenyx Pharmaceutical beats Travere Therapeutics on 12 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$801.52M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-7.448.4026.7219.60Price / Sales4.57258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book3.056.416.764.50Net Income-$146.43M$143.73M$3.23B$248.40M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$15.70-5.4%N/A+153.0%$801.52M$175.34M-7.44221High Trading VolumeRAREUltragenyx Pharmaceutical3.9451 of 5 stars$36.19+1.6%$90.93+151.3%-13.6%$3.42B$590.69M-5.711,310Positive NewsMTSRMetseraN/A$28.96-1.9%$47.00+62.3%N/A$3.10BN/A0.0081Gap DownVKTXViking Therapeutics4.4062 of 5 stars$27.50-3.3%$87.15+216.9%-56.0%$3.09BN/A-27.5020Positive NewsGap DownAKROAkero Therapeutics3.6896 of 5 stars$38.14-1.9%$82.33+115.9%+138.9%$3.04BN/A-10.1730Insider TradeGap DownCPRXCatalyst Pharmaceuticals4.6359 of 5 stars$24.63+1.1%$32.29+31.1%+49.4%$3.00B$534.65M20.8780Positive NewsCRNXCrinetics Pharmaceuticals3.4557 of 5 stars$30.95-0.9%$73.00+135.9%-40.4%$2.90B$760,000.00-8.30210Positive NewsMRUSMerus3.2215 of 5 stars$41.36-0.5%$84.54+104.4%-4.1%$2.86B$54.73M-10.4737Trending NewsAnalyst ForecastOptions VolumeGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.3732 of 5 stars$45.57+2.4%$65.44+43.6%+44.8%$2.82B$207.80M17.13120Positive NewsMLTXMoonLake Immunotherapeutics3.1507 of 5 stars$39.20+4.2%$78.71+100.8%-3.5%$2.51BN/A-30.392Positive NewsGap Up Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Alternatives Metsera Alternatives Viking Therapeutics Alternatives Akero Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Crinetics Pharmaceuticals Alternatives Merus Alternatives MorphoSys Alternatives Protagonist Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTRX Stock Free RTRX Stock Alerts